|
- 奥比妥珠单抗 和 MMF 和 强的松 在 狼疮性肾炎-临床试验 . . .
ICH GCP 美国临床试验注册处 临床试验 NCT04221477 一项评估 Obinutuzumab 在 ISN RPS 2003 III 类或 IV 类狼疮性肾炎患者中的疗效和安全性的研究 (REGENCY) 2025年4月8日 更新者： Hoffmann-La Roche
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Conclusions: Among adults with active lupus nephritis, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete renal response (Funded by F Hoffmann-La Roche; REGENCY ClinicalTrials gov number, NCT04221477 ) Copyright © 2025 Massachusetts Medical Society
- ClinicalTrials. gov
Study record managers: refer to the Data Element Definitions if submitting registration or results information
- OP0006 OBINUTUZUMAB DEMONSTRATES CONSISTENT BENEFIT ACROSS NUMEROUS . . .
The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab over placebo in achieving complete renal response (CRR) at Week 76 when added to standard therapy in patients with active LN
- RESULTS FROM THE REGENCY TRIAL ASSESSING EFFICACY AND SAFETY OF . . .
The results of the Phase III REGENCY trial ( [NCT04221477] [2]), performed to verify NOBILITY, are presented here Methods REGENCY, a Phase III, double-blind placebo-controlled trial, randomized adults with biopsy-proven active proliferative LN 1:1 to placebo or one of 2 intravenous obinutuzumab dosing schedules (1000 mg: Day 1, Weeks 2, 24, 26
- A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients . . .
A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN RPS 2003 Class III Or IV Lupus Nephritis Trial ID: NCT04221477 Age - 18 Years-75 Years Gender - ALL Accepting Healthy Volunteers - No
- New England Journal of Medicine publishes new data for Roche’s Gazyva . . .
About the REGENCY study REGENCY [NCT04221477] is a phase III, randomised, double-blind, placebo-controlled, multicentre study investigating the efficacy and safety of Gazyva® Gazyvaro® (obinutuzumab) plus standard therapy (mycophenolate mofetil and glucocorticoids) in people with active chronic International Society of Nephrology Renal
- Phase III REGENCY Trial Confirms Gazyva Gazyvaro Significantly Improves . . .
Updated results from the Phase III REGENCY trial (NCT04221477) show that patients with lupus nephritis administered Gazyva Gazyvaro (obinutuzumab) plus standard therapy achieved a statistically significant and clinically meaningful improvement in complete renal response (CRR) compared to standard therapy alone 1,2 The trial data, also
|
|
|